http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Jul 2026 06:47:52 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Ionis+Pharmaceuticals+%28IONS%29+PT+Lowered+to+%2489+at+Guggenheim/26791861.html (Updated - July 21, 2026 6:47 AM EDT) <p>Guggenheim analyst Debjit Chattopadhyay lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $89.00 (from $106.00) while maintaining a Buy rating.</p><p>The analyst commented: "Our 2Q26 revenue estimates are slightly above consensus ($209M, -54% YoY, vs. $187M), driven by higher estimates for R&D collaboration revenue ($110M vs. $83M consensus); we included the $30M upfront payment from the license agreement with Recordati (REC.MI) for ex-U.S. zilganersen sales disclosed on Jun 25, 2026. On Tryngolza, we and consensus expect substantial revenue contraction in line with company guidance following the WAC change from $595k to $40k, http://www.streetinsider.com/Analyst+PT+Change/Ionis+Pharmaceuticals+%28IONS%29+PT+Lowered+to+%2489+at+Guggenheim/26791861.html Tue, 21 Jul 2026 06:47:52 -0400 IONS http://www.streetinsider.com/Analyst+Comments/Ionis+Pharmaceuticals+%28IONS%29+PT+Lowered+to+%2489+at+Guggenheim/26791861.html (Updated - July 21, 2026 6:47 AM EDT) <p>Guggenheim analyst Debjit Chattopadhyay lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $89.00 (from $106.00) while maintaining a Buy rating.</p><p>The analyst commented: "Our 2Q26 revenue estimates are slightly above consensus ($209M, -54% YoY, vs. $187M), driven by higher estimates for R&D collaboration revenue ($110M vs. $83M consensus); we included the $30M upfront payment from the license agreement with Recordati (REC.MI) for ex-U.S. zilganersen sales disclosed on Jun 25, 2026. On Tryngolza, we and consensus expect substantial revenue contraction in line with company guidance following the WAC change from $595k to $40k, http://www.streetinsider.com/Analyst+Comments/Ionis+Pharmaceuticals+%28IONS%29+PT+Lowered+to+%2489+at+Guggenheim/26791861.html Tue, 21 Jul 2026 06:47:52 -0400 IONS http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+HERMAN+JOAN+E/26785129.html si-local-file:///var/storage/secattach/20260717/26785129.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+HERMAN+JOAN+E/26785129.html Fri, 17 Jul 2026 17:13:00 -0400 IONS O.00134870 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+HERMAN+JOAN+E/26785129.html si-local-file:///var/storage/secattach/20260717/26785129.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+HERMAN+JOAN+E/26785129.html Fri, 17 Jul 2026 17:13:00 -0400 IONS O.00134870 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+HANTSON+LUDWIG/26785133.html si-local-file:///var/storage/secattach/20260717/26785133.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+HANTSON+LUDWIG/26785133.html Fri, 17 Jul 2026 17:13:00 -0400 IONS O.00134870 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+HANTSON+LUDWIG/26785133.html si-local-file:///var/storage/secattach/20260717/26785133.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+HANTSON+LUDWIG/26785133.html Fri, 17 Jul 2026 17:13:00 -0400 IONS O.00134870 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+Reikes+Peter+N/26785136.html si-local-file:///var/storage/secattach/20260717/26785136.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+Reikes+Peter+N/26785136.html Fri, 17 Jul 2026 17:13:00 -0400 IONS O.00134870 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+Reikes+Peter+N/26785136.html si-local-file:///var/storage/secattach/20260717/26785136.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+Reikes+Peter+N/26785136.html Fri, 17 Jul 2026 17:13:00 -0400 IONS O.00134870 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+BERTHELSEN+SPENCER+R/26785125.html si-local-file:///var/storage/secattach/20260717/26785125.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+BERTHELSEN+SPENCER+R/26785125.html Fri, 17 Jul 2026 17:12:00 -0400 IONS O.00134870 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+BERTHELSEN+SPENCER+R/26785125.html si-local-file:///var/storage/secattach/20260717/26785125.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+15++Filed+by%3A+BERTHELSEN+SPENCER+R/26785125.html Fri, 17 Jul 2026 17:12:00 -0400 IONS O.00134870 http://www.streetinsider.com/Downgrades/Wolfe+Research+Downgrades+Ionis+Pharmaceuticals+%28IONS%29+to+Peerperform/26775433.html <p>Wolfe Research analyst Andy Chen downgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Outperform to Peerperform.</p><p>The analyst comments: “Downgrade IONS to Peer Perform. Fair value range $49-$79/share but stock unlikely to close in to this the upper end of the range. On the PT range, the upper end is supported by our DCF valuation. The bottom end accounts for the worst case scenario where Arrowhead succeeds and Lp(a) fails, while the rest of the stock remains stagnant.</p><p>Longer-term IONS may perform well on sHTG and potentially Angelman. We model $4.5B Tryngolza peak sales (vs buyside $2.5B), which is enough to support more than http://www.streetinsider.com/Downgrades/Wolfe+Research+Downgrades+Ionis+Pharmaceuticals+%28IONS%29+to+Peerperform/26775433.html Thu, 16 Jul 2026 02:22:53 -0400 IONS http://www.streetinsider.com/Analyst+Comments/Wolfe+Research+Downgrades+Ionis+Pharmaceuticals+%28IONS%29+to+Peerperform/26775433.html <p>Wolfe Research analyst Andy Chen downgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Outperform to Peerperform.</p><p>The analyst comments: “Downgrade IONS to Peer Perform. Fair value range $49-$79/share but stock unlikely to close in to this the upper end of the range. On the PT range, the upper end is supported by our DCF valuation. The bottom end accounts for the worst case scenario where Arrowhead succeeds and Lp(a) fails, while the rest of the stock remains stagnant.</p><p>Longer-term IONS may perform well on sHTG and potentially Angelman. We model $4.5B Tryngolza peak sales (vs buyside $2.5B), which is enough to support more than http://www.streetinsider.com/Analyst+Comments/Wolfe+Research+Downgrades+Ionis+Pharmaceuticals+%28IONS%29+to+Peerperform/26775433.html Thu, 16 Jul 2026 02:22:53 -0400 IONS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+07++Filed+by%3A+BENNETT+C+FRANK/26772894.html si-local-file:///var/storage/secattach/20260715/26772894.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+07++Filed+by%3A+BENNETT+C+FRANK/26772894.html Wed, 15 Jul 2026 11:53:00 -0400 IONS O.00134870 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+07++Filed+by%3A+BENNETT+C+FRANK/26772894.html si-local-file:///var/storage/secattach/20260715/26772894.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IONIS+PHARMACEUTICALS+++++For%3A+Jul+07++Filed+by%3A+BENNETT+C+FRANK/26772894.html Wed, 15 Jul 2026 11:53:00 -0400 IONS O.00134870 http://www.streetinsider.com/Press+Releases/Ionis+to+hold+second+quarter+2026+financial+results+webcast/26770751.html <p class="bwalignc"><i>Webcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern Time</i></p> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results and highlight progress on key programs.</p><p class="bwalignl">The webcast may be accessed at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.ionis.com%2Fevents-and-presentations%2Fupcoming-events&amp;esheet=54570748&amp;newsitemid=20260715218889&amp;lan=en-US&amp;anchor=https%3A%2F%2Fir.ionis.com%2Fevents-and-presentations%2Fupcoming-events&amp;index=1&amp;md5=1d6480da8470831624bcba3feccef81d" shape="rect">https://ir.ionis.com/events-and-presentations/upcoming-events</a>. A replay will be available for a limited time at the same address.</p><p><b>About Ionis Pharmaceuticals, Inc.</b></p><p>For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has http://www.streetinsider.com/Press+Releases/Ionis+to+hold+second+quarter+2026+financial+results+webcast/26770751.html Wed, 15 Jul 2026 07:05:00 -0400 IONS O.00134870 http://www.streetinsider.com/Press+Releases/Ionis+to+hold+second+quarter+2026+financial+results+webcast/26770751.html <p class="bwalignc"><i>Webcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern Time</i></p> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results and highlight progress on key programs.</p><p class="bwalignl">The webcast may be accessed at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.ionis.com%2Fevents-and-presentations%2Fupcoming-events&amp;esheet=54570748&amp;newsitemid=20260715218889&amp;lan=en-US&amp;anchor=https%3A%2F%2Fir.ionis.com%2Fevents-and-presentations%2Fupcoming-events&amp;index=1&amp;md5=1d6480da8470831624bcba3feccef81d" shape="rect">https://ir.ionis.com/events-and-presentations/upcoming-events</a>. A replay will be available for a limited time at the same address.</p><p><b>About Ionis Pharmaceuticals, Inc.</b></p><p>For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has http://www.streetinsider.com/Press+Releases/Ionis+to+hold+second+quarter+2026+financial+results+webcast/26770751.html Wed, 15 Jul 2026 07:05:00 -0400 IONS O.00134870 http://www.streetinsider.com/Business+Wire/Ionis+to+hold+second+quarter+2026+financial+results+webcast/26770751.html <p class="bwalignc"><i>Webcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern Time</i></p> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results and highlight progress on key programs.</p><p class="bwalignl">The webcast may be accessed at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.ionis.com%2Fevents-and-presentations%2Fupcoming-events&amp;esheet=54570748&amp;newsitemid=20260715218889&amp;lan=en-US&amp;anchor=https%3A%2F%2Fir.ionis.com%2Fevents-and-presentations%2Fupcoming-events&amp;index=1&amp;md5=1d6480da8470831624bcba3feccef81d" shape="rect">https://ir.ionis.com/events-and-presentations/upcoming-events</a>. A replay will be available for a limited time at the same address.</p><p><b>About Ionis Pharmaceuticals, Inc.</b></p><p>For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has http://www.streetinsider.com/Business+Wire/Ionis+to+hold+second+quarter+2026+financial+results+webcast/26770751.html Wed, 15 Jul 2026 07:05:00 -0400 IONS O.00134870